Robert Levy
Optometrist · Burlington, NJNPI 1861495517
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,250 of the $23,571 with a category attached, or 73.2%. LKC Technologies, Inc. accounts for 73.2% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $18,154 and has fallen 94.3% since, to $1,026 in 2025. Among optometrist clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $72.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- LKC Technologies, Inc.$17K
- Alcon$808
- AbbVie$747
- Bausch & Lomb Americas Inc.$735
- Johnson & Johnson Vision Care, Inc.$557
- Novartis$475
- plus $3K from 19 others
What the payments were for
- Speaking & faculty fees$17,25073%
- Travel & lodging$2761%
- Food & beverage$6,02826%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| LKC Technologies, Inc. | 1 | $17,250 |
| Alcon | 34 | $808 |
| AbbVie(2 entities) | 43 | $747 |
| Bausch & Lomb Americas Inc. | 48 | $735 |
| Johnson & Johnson Vision Care, Inc. | 18 | $557 |
| Novartis | 34 | $475 |
| Sun Pharmaceutical Industries Inc. | 19 | $303 |
| Oyster Point Pharma, Inc. | 21 | $303 |
| Dompe US, Inc. | 12 | $292 |
| Kala Pharmaceuticals, Inc. | 14 | $283 |
| Vertos Medical, Inc. | 1 | $276 |
| ABB Con-cise Optical Group LLC | 12 | $254 |
| Rxsight Inc | 4 | $231 |
| Tarsus Pharmaceuticals, Inc. | 14 | $211 |
| Aerie Pharmaceuticals, Inc. | 11 | $172 |
| Amgen(2 entities) | 9 | $154 |
| Coopervision Inc. | 9 | $147 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $139 |
| Sight Sciences, Inc. | 1 | $114 |
| Eyevance Pharmaceuticals LLC | 3 | $40 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Visioneering Technologies, Inc. | 1 | $17 |
| Maculogix, Inc. | 1 | $16 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Harrow Eye, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RETeval Complete$17,250
- mild Device Kit$276
- Acuvue$256
- TRYPTYR$125
- MIEBO$124
- XIIDRA$124
- OMNI(R) SURGICAL SYSTEM (US)$114
- Oxervate$109
- LUMIGAN$107
- TOTAL30$102
How this compares
$23,571 in reported general payments places this provider in the 95th percentile of 1,357 optometrist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 204 | $163,338 |
| XiidraLifitegrast | 106 | $111,452 |
| MieboPerfluorohexyloctane/Pf | 55 | $44,403 |
| LumiganBimatoprost | 83 | $34,401 |
| Cyclosporine | 66 | $26,754 |
| VyzultaLatanoprostene Bunod | 26 | $16,989 |
| CombiganBrimonidine Tartrate/Timolol | 28 | $14,120 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 94 | $13,790 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $9,167 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $7,886 |
| Restasis MultidoseCyclosporine | 12 | $7,725 |
| Latanoprost | 550 | $5,854 |
| Prednisolone Acetate | 113 | $4,945 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 123 | $2,524 |
| Travoprost | 13 | $1,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose | $747 | $219,584327 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $735 | $172,844187 claims |
| AlconSimbrinza | $808 | $9,16722 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $172 | $7,88614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 optometrist providers in New Jersey.
Other optometrist in Burlington
- Kerry GelbWoodbridge$264K
- Rodolfo RodriguezNorth Bergen$244K
- Steven SorkinFairfield$146K
- Paul VaccarellaRockaway$99K
- Ada NohCinnaminson$74K
- Melanne RosettaIselin$66K
- Frank BuccieroSpringfield$57K
- Victoria DzurinkoDeptford$47K
- Michael McAleeseHowell$33K
- Gary RochaParamus$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.